News | May 03, 2025
Zydus Lifesciences completes 25 years of listing on NSE
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This significant milestone enhances our global regulatory standing
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Subscribe To Our Newsletter & Stay Updated
